TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04019366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training
Description: Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
Study: NCT02274337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: patients take avitinib orally once per day at different dose
Study: NCT00602355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care.
Study: NCT03473223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Apolipoprotein A-I [human] (apoA-I)
Description: Apolipoprotein A-I \[human\] (apoA-I) purified from human plasma for intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25% albumin solution diluted to 4.4%
Study: NCT06628843

Intervention type: OTHER
Intervention: cesarean section rate
Description: Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries

Intervention type: OTHER
Intervention: cesarean section rate
Description: Incidence of cesarean sections in the two periods, Rate of adverse outcomes within vaginal and cesarean deliveries
Study: NCT03539822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: infusion
Study: NCT02839161

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-APR-1 (M74)/Alhydrogel

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine
Study: NCT00602355

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal psychotherapy (IPT)
Description: IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical management
Description: Clinical management includes treatment as usual for those receiving medication for depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical management
Description: Clinical management includes treatment as usual for those receiving medication for depression.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mothercrafting
Description: Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mothercrafting
Description: Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
Study: NCT00649103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril Hydrochloride Tablets 40 mg
Description: 40mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accupril® Tablets 40 mg
Description: 40mg, single dose fasting
Study: NCT03258554

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04219228

Intervention type: DIAGNOSTIC_TEST
Intervention: Ophthalmic examinations
Description: Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ophthalmic examinations
Description: Ophthalmic examinations include visual acuity, cover test and ocular dominance, noncycloplegic autorefraction, cycloplegia, ocular biometric measurements, cycloplegic auto-refraction, subjective refraction, and anterior and posterior segment examination.

Intervention type: DEVICE
Intervention: Wearable devices
Description: Physical activity, light intensity, and visual information will be measured with wearable devices.

Intervention type: DEVICE
Intervention: Wearable devices
Description: Physical activity, light intensity, and visual information will be measured with wearable devices.
Study: NCT03860948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib Test Preparation
Description: Test preparation (T): dry granulation savolitinib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib Reference Preparation
Description: Reference preparation (R): wet granulation savolitinib tablets.
Study: NCT03439033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/MRI with Gallium-68 labeled PSMA-HBED-CC
Description: Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC
Description: Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT with Gallium-68 labeled PSMA-HBED-CC
Description: Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
Study: NCT01560273

Intervention type: DEVICE
Intervention: Aspen Spinous Process Fixation Device
Description: The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
Study: NCT04611022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Educational Intervention
Description: The videos are 8-minute narrative films created using an entertainment-education (E-E) approach that embeds an educational narrative message into an entertainment format such as media. E-E narratives have demonstrated a significant effect (r = .12, p \< .001) on health behavior change. Evidence-based small media interventions that Dr. Borrayo has produced include videos that are highly verbal, visual, and entertaining (e.g., acted fictional stories). The aims of the video will be to model uptake of the HPV vaccine, but also to reinforce self-efficacy, subjective norms, and behavioral intentions, all significant precursors to behavior change.
Study: NCT02748161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB-TACE
Description: Transarterial chemoembolization with doxorubicin-eluting beads.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB-TACE
Description: Transarterial chemoembolization with doxorubicin-eluting beads.
Study: NCT01787708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red light

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red light
Study: NCT00654264

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Water immersion
Description: Subjects will sit in tub for four hours.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Water immersion
Description: Subjects will sit in tub for four hours.
Study: NCT02679053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Study: NCT00892554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid
Description: Capsules providing 10 mg DHA/kg body weight/day taken once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn/soy oil
Description: Capsules taken once daily
Study: NCT01500057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight XPS Laser
Description: Treatment of BPH with Greenlight XPS laser
Study: NCT03316001

Intervention type: OTHER
Intervention: Review of multidetector row computed tomography scans
Description: multidetector row computed tomography scans

Intervention type: OTHER
Intervention: Review of multidetector row computed tomography scans
Description: multidetector row computed tomography scans
Study: NCT01973348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-hour AmblyZ glasses
Description: 4-hour AmblyZ glasses for moderate amblyopia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-hour AmblyZ glasses
Description: 12-hour AmblyZ glasses for severe amblyopia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-hour patching
Description: 2-hour patching for moderate amblyopia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6-hour patching
Description: 6-hour patching for severe amblyopia
Study: NCT01313949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training program
Description: These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program \[NLP\] trainer to ensure the adequacy of knowledge and skills of these mentors.
Study: NCT01790204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Watercress Juice
Description: The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
Study: NCT01853553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Blood pressure medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Placebo.
Study: NCT03982485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
Study: NCT01500057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiVAP Saline Vaporization of the prostate
Description: treatment of BPH with BiVAP Saline Vaporization
Study: NCT03982485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery
Study: NCT02606994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Defense Toothpaste
Description: Brush with a Oral Defense Toothpaste three times per day during the study
Study: NCT01037283

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Interpersonal and Social Rhythm Therapy
Description: Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
Study: NCT02606994

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crest Toothpaste
Description: Brush with Crest Toothpaste three times per day during the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magic Mouth Rinse
Description: Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
Study: NCT02005120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intrapleural administration of bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: Intrapleural administration of recombinant human endostatin
Study: NCT05699720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Magnesium Sulphate
Description: Group A received 250mg of MgSO4 /dose given through nebulizer four times a day, while group B did not. The groups will be followed for five days to see the results in terms of in-hospital outcome, whether the patient is discharged after fulfilling the set criteria or needing assisted ventilation.
Study: NCT00732095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Self-Change with Ads
Description: Use of Ads immediate or delayed or no ad
Study: NCT02015390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous RIA bone grafting
Description: After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous RIA bone grafting
Description: After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include autogenous bone grafting harvesting using Reamer-Irrigator-Aspirator (RIA) and packing it within the defect.
Study: NCT00354601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral capecitabine twice daily on days 1-21
Study: NCT02015390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic bone grafting
Description: After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic bone grafting
Description: After aseptic defect and adequate soft tissue coverage have been achieved, the defect reconstruction technique will include defect packing with allogeneic bone graft croutons combined with demineralized bone matrix (DBM).
Study: NCT01213901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Description: Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
Study: NCT00354601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel IV over 30 minutes on days 1, 8, and 15
Study: NCT02048111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IB1001
Description: Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator.
Study: NCT02291562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: 10 mg Tetrahydrocannabinol (capsule, once) oral intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: 600 mg Cannabidiol (capsule, once) oral intake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (capsule, once) oral intake
Study: NCT05116124

Intervention type: OTHER
Intervention: dosing of inflammatory parameters
Description: View and register the dosing of inflammatory parameters
Study: NCT00555230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
Study: NCT00949312

Intervention type: GENETIC
Intervention: RNA marker analysis of lymph node and primary tumors

Intervention type: GENETIC
Intervention: microarray profiling of primary tumors
Study: NCT00949312

Intervention type: GENETIC
Intervention: reverse transcriptase-polymerase chain reaction of lymph node specimens

Intervention type: OTHER
Intervention: diagnostic laboratory RNA and DNA biomarker analysis of primary tumors

Intervention type: PROCEDURE
Intervention: regional lymph node dissection

Intervention type: OTHER
Intervention: lymph node staining for H&E and pancytokeratin IHC
Study: NCT02202486

Intervention type: OTHER
Intervention: Brain MRI
Description: Brain MRI with gadolinium contrast

Intervention type: OTHER
Intervention: Brain MRI
Description: Brain MRI with gadolinium contrast

Intervention type: OTHER
Intervention: Brain MRI
Description: Brain MRI with gadolinium contrast
Study: NCT03354221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEsAI Pro
Description: This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Likert Scoring Scale
Description: This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience.
Study: NCT02898545

Intervention type: DEVICE
Group type: OTHER
Intervention: SEEQ monitor
Description: An external cardiac rhythm monitor
Study: NCT01959256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual perceptual learning
Description: 24 times of training for visual perceptual learning
Study: NCT01958463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota transplantation.
Description: Fecal Microbiota transplantation during colonoscopy.